Twist Bioscience Partners with Invetx to Deliver Best-in-Class Antibody Therapeutics for Dogs and Cats
July 17, 2020
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Invetx, a pioneer in protein-based therapeutics for animal health, today announced a partnership for the engineering and optimization of novel antibodies for the treatment of serious diseases in dogs and cats.
“Many diseases in animals manifest through the same protein targets observed in humans,” said Juergen Horn, PhD, chief executive officer of Invetx. “By partnering with Twist to create specific antibody libraries for veterinary species, we are expanding Invetx’s ability to deliver best-in-class antibody therapeutics and translate biotechnology approaches already proven successful in the human field to veterinary medicine.”
Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will use its Twist Antibody Optimization (TAO) platform to engineer and optimize multiple antibodies against important disease targets in animal health. The Twist technology will be a key component of Invetx’s antibody discovery effort and the company’s strategy to develop safer and more effective veterinary medicines.
“Leading market research firms estimate the global animal medicines market was nearly $34 billion in 2019, with a compound annual growth rate of five to seven percent,” said Emily M. Leproust, PhD, chief executive officer and co-founder of Twist Bioscience. “With the high degree of genetic conservation between species, we believe Invetx’s approach to bring the best of biopharma to animal health has incredible possibilities to offer improved therapeutics to our pets. We look forward to being an integral part of Invetx’s effort to revolutionize the medicines available to the animal health industry.”
Invetx is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. In February 2020, the company announced a $15 million Series A financing and strategic partnerships with AbCellera, a biotech company specializing in antibody discovery located in Vancouver, BC and WuXi Biologics, a global company with leading biologics technology platforms. Invetx is a private company headquartered in Boston, Massachusetts. For more information, see invetx.com.
About Twist Bioscience
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including diagnostics, therapeutics, industrial chemicals, agriculture and academic research. For more information visit www.twistbioscience.com and www.twistbiopharma.com.